Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Sonic Foundry completes $11.25M stock offer
4. Orion Energy completes $5M capital round
5. RedPrairie completes MARC acquisition
6. Metavante completes purchase of check processing firm
7. GE completes $1.2 billion acquisition
8. M & Is Metavante completes Brasfield Corp. acquisition
9. Metavante completes GHR Systems acquisition
10. Metavante completes TREEV acquisition
11. Johnson Controls completes sale of French unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... deal from January through March this year, according to the ... state said that the lack of deals in a quarter ... another reminder that capital is hard to come by. , ... sometimes adding up to around $20 million or $25 million, ...
... America's health care costs continue to rise, the need ... potential of the Internet has never been more urgent. ... Exchange (WHIE) has joined more than 150 statewide ... task of creating localized systems in which clinics, hospitals, ...
... , ,Two companies enter into an agreement to develop software, ... service provider deliver a range of services in the information ... the parties come to the end of the engagement reasonably ... , ,However, sometimes the agreement goes astray and disputes ...
Cached Biology Technology:Money Tree survey shows lull in Wisconsin venture capital deals 2Money Tree survey shows lull in Wisconsin venture capital deals 3Wisconsin Health Information Exchange shares burden of electronic medical records 2Wisconsin Health Information Exchange shares burden of electronic medical records 3Wisconsin Health Information Exchange shares burden of electronic medical records 4Wisconsin Health Information Exchange shares burden of electronic medical records 5Arbitration can help when IT deals go sour 2Arbitration can help when IT deals go sour 3
(Date:7/9/2014)... With over 100 diseases that can attack soybean ... of the most wanted list? University of Illinois scientists ... more research is needed on the fungus that causes ... cool, damp growing conditions but Macrophomina phaseolina , ... dry drought conditions. , "As the climate continues to ...
(Date:7/9/2014)... cooks are turning to more healthful alternatives to their ... sometimes mean low satisfaction. Now researchers are reporting new ... that are made with olive oil rather than pork ... of Agricultural and Food Chemistry . , Ana M. ... to expect just the right amount of chewiness and ...
(Date:7/9/2014)... of Adlie penguins shows that the population is ... than previously estimated. Adlie penguins have long been ... understand the effects of climate change and fishing ... satellite imagery, researchers from Stony Brook University and ... that permits regular monitoring of Adlie penguins across ...
Breaking Biology News(10 mins):Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... modeling and paleontological evidence as a crystal ball, 18 ... on a much worse collision course with Mother Nature ... state-shift in Earth,s biosphere, a paper just published in ... multitude of disciplines, suggest our planet,s ecosystems are careening ...
... that live zebrafish can be influenced by engineered robots. ... Bioinspiration and Biomimetics , provide a stepping stone on the ... monitor and control fish behaviour. In the future, water-based ... and the control of pest species. ...
... Researchers who were looking for organisms that eke out ... Earth have found a hardy few. A new DNA analysis ... in South America has revealed a handful of bacteria, fungi, ... a different way of converting energy than their cousins elsewhere ...
Cached Biology News:Study predicts imminent irreversible planetary collapse 2Engineered robot interacts with live fish 2AGU: Unique microbes found in extreme environment 2AGU: Unique microbes found in extreme environment 3AGU: Unique microbes found in extreme environment 4
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Request Info...
Mouse monoclonal [J53] to Thyroid Hormone Receptor beta 1 ( Abpromise for all tested applications). entrezGeneID: 7068 SwissProtID: P10828...
Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
Biology Products: